359 related articles for article (PubMed ID: 15269478)
1. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas.
Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C
Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478
[TBL] [Abstract][Full Text] [Related]
2. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
4. Microvessel density in brain tumors.
Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Papadakis N; Varakis I
Anticancer Res; 1997; 17(6D):4747-53. PubMed ID: 9494601
[TBL] [Abstract][Full Text] [Related]
5. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
Kamiya M; Nakazato Y
Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253
[TBL] [Abstract][Full Text] [Related]
6. Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry.
Badhe PB; Chauhan PP; Mehta NK
Indian J Cancer; 2004; 41(4):170-4. PubMed ID: 15659871
[TBL] [Abstract][Full Text] [Related]
7. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
8. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas.
Lang FF; Miller DC; Pisharody S; Koslow M; Newcomb EW
Oncogene; 1994 Mar; 9(3):949-54. PubMed ID: 8108140
[TBL] [Abstract][Full Text] [Related]
9. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system.
Sasaki T; Lopes MB; Hankins GR; Helm GA
Acta Neuropathol; 2002 Jul; 104(1):105-9. PubMed ID: 12070671
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of malignant features in oligodendroglial tumors.
Saito A; Nakazato Y
Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700
[TBL] [Abstract][Full Text] [Related]
11. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
Prayson RA; Mohan DS; Song P; Suh JH
Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299
[TBL] [Abstract][Full Text] [Related]
13. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
14. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
15. p53 mutation and protein alteration in 50 gliomas. Retrospective study by DNA-sequencing techniques and immunohistochemistry.
von Eckardstein K; Gries H; Bolik E; Cervós-Navarro J; Tschairkin IN; Patt S
Histol Histopathol; 1997 Jul; 12(3):611-6. PubMed ID: 9225141
[TBL] [Abstract][Full Text] [Related]
16. [Histological and molecular classification of gliomas].
Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
[TBL] [Abstract][Full Text] [Related]
17. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H
Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
[TBL] [Abstract][Full Text] [Related]
18. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
Erdamar S; Bagci P; Oz B; Dirican A
J BUON; 2006; 11(2):213-6. PubMed ID: 17318973
[TBL] [Abstract][Full Text] [Related]
19. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas.
Thorns V; Walter GF; Thorns C
Anticancer Res; 2003; 23(5A):3937-44. PubMed ID: 14666700
[TBL] [Abstract][Full Text] [Related]
20. Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.
Haapasalo H; Isola J; Sallinen P; Kalimo H; Helin H; Rantala I
Am J Pathol; 1993 May; 142(5):1347-51. PubMed ID: 7684193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
